Beam Therapeutics Announces Key R&D Appointments
16 3월 2020 - 8:00PM
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company
developing precision genetic medicines through base editing, today
announced key leadership appointments, including the promotion of
Manmohan Singh, Ph.D., from vice president to senior vice president
of pharmaceutical sciences and delivery technologies, and the
appointment of Christine Swenson as senior vice president of
regulatory affairs.
“As we advance our new class of precision genetic medicines
closer to the clinic, we are focused on continuing to expand the
scientific leadership at Beam,” said John Evans, chief executive
officer of Beam. “We look forward to benefitting from Chris and
Mano’s decades of experience in developing innovative new therapies
at leading companies. Their leadership will help us deliver
precise, predictable and efficient base editing medicines that have
the potential to become life-long cures for patients with serious
diseases.”
Dr. Singh has over 25 years of drug discovery and development
experience in vaccines, biologics and small molecules. Prior to
joining Beam, he was the global head of formulation and drug
product development for Takeda Vaccines, where he oversaw teams of
scientists in Cambridge, Japan and Europe. Prior to joining Takeda,
Dr. Singh was at Novartis Vaccines, where, amongst other
contributions, he played a pivotal role in the development of the
lipid nanoparticle technology that was eventually licensed to
Intellia. Dr. Singh has published more than 120 peer-reviewed
articles, reviews and book chapters, and he is an adjunct professor
at the University of North Carolina at Chapel Hill and at
Northeastern University in Boston. Dr. Singh earned his Ph.D. from
the National Institute of Immunology in New Delhi, India and his
MPharm from Sagar University, India.
Ms. Swenson has more than 30 years of drug development
experience, including extensive leadership of domestic and
international regulatory affairs spanning early- and clinical-stage
development of both biologics and small molecules across multiple
therapeutic areas. Before joining Beam, she was the senior vice
president, global regulatory affairs at Moderna, where she led the
development and execution of regulatory strategies for its
portfolio of mRNA therapeutics and vaccines. Prior to Moderna, Ms.
Swenson held leadership roles in regulatory affairs, which included
global regulatory lead for the Yervoy and Opdivo immuno-oncology
programs at Bristol-Myers Squibb, Adnexus, ImmunoGen and Coley
Pharmaceutical Group. Ms. Swenson received a B.S. in biology from
Stonehill College.
About Beam TherapeuticsBeam
Therapeutics (Nasdaq: BEAM) is a biotechnology company
developing precision genetic medicines through the use of base
editing. Beam’s proprietary base editors create precise,
predictable and efficient single base changes, at targeted genomic
sequences, without making double-stranded breaks in the DNA. This
enables a wide range of potential therapeutic editing strategies
that Beam is using to advance a diversified portfolio of base
editing programs. Beam is a values-driven organization focused on
its people, cutting-edge science, and a vision of providing
life-long cures to patients suffering from serious diseases. For
more information, visit www.Beamtx.com.
Contacts:
Media:Dan Budwick1ABdan@1abmedia.com
Investors:Monique AllaireTHRUST Strategic
Communicationsmonique@thrustsc.com
Beam Therapeutics (NASDAQ:BEAM)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Beam Therapeutics (NASDAQ:BEAM)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024